The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Nuclear Medicine Diagnostics Market From 2026 To 2030?
The nuclear medicine diagnostics market has shown rapid expansion in recent years. Its valuation is expected to rise from $7.88 billion in 2025 to $8.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.2%. This historical development is primarily due to factors such as the increasing application of radioactive tracers in diagnostics, the establishment of more hospital-based nuclear medicine units, a growing need for functional imaging, the widespread availability of technetium-based radiopharmaceuticals, and an increase in clinical research activities within nuclear medicine.
The nuclear medicine diagnostics market size is projected for swift expansion in the upcoming years, with its valuation set to reach $13.77 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth is driven by factors such as increased investments in theranostics, the growing embrace of precision oncology diagnostics, the expansion of PET imaging infrastructure, a heightened focus on developing targeted radiopharmaceuticals, and enhanced regulatory backing for nuclear diagnostics. Key trends during this period encompass the increasing acceptance of PET-based diagnostic radiopharmaceuticals, a surging demand for personalized nuclear diagnostics, the expanding integration of imaging and therapeutic applications, the proliferation of oncology-focused nuclear medicine procedures, and an intensified concentration on short-half-life radiotracers.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9415&type=smp
What Key Drivers Are Influencing The Growth Of The Nuclear Medicine Diagnostics Market?
The escalating occurrence of cancer is anticipated to boost the expansion of the nuclear medicine diagnostics market in the coming years. Cancer is defined as a group of diseases marked by the uncontrolled multiplication and spread of abnormal cells within the body, often forming a mass or lump known as a tumor. The increased prevalence of cancer can be attributed to the aging global population, as cancer incidence rises considerably with age, while improved healthcare extends life expectancy. Nuclear medicine diagnostics plays a crucial role in the detection, staging, and monitoring of various types of cancer, utilizing radioactive substances that specialized cameras can detect to generate detailed images of the internal structures and functions of organs and tissues. For instance, in May 2025, according to the National Cancer Institute, a US-based intergovernmental organization, in 2022, nearly 20 million people were diagnosed with cancer and 9.7 million died from it, and by 2050 these figures are projected to climb to 33 million new cases and 18.2 million deaths annually. This surge in cancer cases is thus propelling the growth of the nuclear medicine diagnostics market.
Which Segments Are Included In The Analysis Of The Nuclear Medicine Diagnostics Market?
The nuclear medicine diagnostics market covered in this report is segmented –
1) By Type: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
2) By Application: Cardiology, Thyroid, Neurology, Oncology, Other Applications
3) By End-User: Hospitals And Diagnostic Centers, Research Institutes
Subsegments:
1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals
2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals
Which Trends Are Impacting The Growth Of The Nuclear Medicine Diagnostics Market?
Leading companies operating in the nuclear medicine diagnostics market are concentrating on rolling out advanced solutions, such as advanced medical technologies, to gain a competitive edge. These advanced medical technologies represent state-of-the-art innovations in the medical field, aimed at improving patient outcomes, elevating the standard of care, and promoting better health. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based entity that provides medical and healthcare services, unveiled its Nuclear Medicine Unit. This nuclear medicine unit is a dedicated facility within a hospital or medical center, equipped with the newest technology and staffed by highly proficient professionals. The primary function of this facility is to enable early detection, diagnosis, and treatment of diseases by utilizing nuclear medicine imaging techniques.
Which Key Industry Participants Are Active In The Nuclear Medicine Diagnostics Market?
Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacibasi-Monrol Nuclear Products Co.
Read the full nuclear medicine diagnostics market report here:
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Nuclear Medicine Diagnostics Market?
North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Nuclear Medicine Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9415&type=smp
Browse Through More Reports Similar to the Global Nuclear Medicine Diagnostics Market 2026, By The Business Research Company
Nuclear Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report
Nuclear Medicine Radioisotopes Market Report 2026
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model